HDAC Inhibitors and Cardiac Safety
Open Access
- 1 February 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (3), 1068
- https://doi.org/10.1158/1078-0432.ccr-06-1715
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine TumorsClinical Cancer Research, 2006
- Phase II study of FK228 in patients with hormone refractory prostate cancer (HRPC)Journal of Clinical Oncology, 2006
- Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell LymphomaClinical Cancer Research, 2006
- Histone Deacetylase Inhibitors: Emerging Anticancer Therapeutic Agents?Clinical Lung Cancer, 2005
- Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignanciesJournal of Clinical Oncology, 2005